 Connection
Brian Freed to Tumor Cells, Cultured
This is a "connection" page, showing publications Brian Freed has written about Tumor Cells, Cultured.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.119 |
|
|
|
-
Lang J, Capasso A, Jordan KR, French JD, Kar A, Bagby SM, Barbee J, Yacob BW, Head LS, Tompkins KD, Freed BM, Somerset H, Clark TJ, Pitts TM, Messersmith WA, Eckhardt SG, Wierman ME, Leong S, Kiseljak-Vassiliades K. Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment. J Clin Endocrinol Metab. 2020 01 01; 105(1).
Score: 0.039
-
Geiselhart L, Conti DJ, Freed BM. RO 31-8220, a novel protein kinase C inhibitor, inhibits early and late T cell activation events. Transplantation. 1996 Jun 15; 61(11):1637-42.
Score: 0.031
-
Gallichio MH, Conti DJ, Lempert N, Gruber SA, Geiselhart L, Freed BM. Calcium-mediated induction of anergy in the Jurkat T-cell line. Transplant Proc. 1994 Dec; 26(6):3458-9.
Score: 0.028
-
Freed BM, Lempert N, Lawrence DA. Inhibition of interleukin-2 production in the human T cell line JURKAT by nonpolar maleimides. Toxicol Appl Pharmacol. 1991 Jan; 107(1):173-82.
Score: 0.021
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|